Nordea Investment Management AB Grows Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Nordea Investment Management AB raised its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 19.1% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 67,546 shares of the biotechnology company’s stock after buying an additional 10,815 shares during the quarter. Nordea Investment Management AB’s holdings in Sarepta Therapeutics were worth $8,228,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Janus Henderson Group PLC grew its holdings in shares of Sarepta Therapeutics by 14.2% in the 3rd quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company’s stock worth $544,408,000 after acquiring an additional 543,143 shares during the period. Wellington Management Group LLP grew its holdings in Sarepta Therapeutics by 32.3% in the third quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock valued at $340,527,000 after purchasing an additional 665,087 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Sarepta Therapeutics by 2.7% in the third quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company’s stock valued at $211,910,000 after buying an additional 44,306 shares in the last quarter. Jacobs Levy Equity Management Inc. raised its stake in shares of Sarepta Therapeutics by 9.2% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 753,845 shares of the biotechnology company’s stock worth $94,148,000 after buying an additional 63,437 shares during the last quarter. Finally, Thrivent Financial for Lutherans boosted its position in shares of Sarepta Therapeutics by 6.3% in the 2nd quarter. Thrivent Financial for Lutherans now owns 644,675 shares of the biotechnology company’s stock worth $101,858,000 after buying an additional 37,940 shares in the last quarter. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

SRPT has been the subject of several recent research reports. Needham & Company LLC dropped their target price on shares of Sarepta Therapeutics from $205.00 to $202.00 and set a “buy” rating for the company in a report on Wednesday, November 27th. Cantor Fitzgerald raised Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and upped their target price for the company from $152.00 to $167.00 in a research note on Thursday, November 7th. Evercore ISI dropped their price target on Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. HC Wainwright restated a “sell” rating and issued a $75.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, December 19th. Finally, StockNews.com cut Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $178.71.

Sarepta Therapeutics Trading Up 1.4 %

Shares of SRPT stock opened at $126.27 on Friday. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics, Inc. has a fifty-two week low of $102.15 and a fifty-two week high of $173.25. The firm’s 50 day moving average price is $122.11 and its two-hundred day moving average price is $131.33. The stock has a market cap of $12.06 billion, a price-to-earnings ratio of 101.02 and a beta of 0.77.

Insider Activity at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 1,636 shares of the business’s stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $125.55, for a total transaction of $205,399.80. Following the transaction, the director now owns 5,880 shares in the company, valued at $738,234. The trade was a 21.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $124.84, for a total value of $1,310,820.00. Following the completion of the sale, the director now owns 22,840 shares of the company’s stock, valued at approximately $2,851,345.60. This trade represents a 31.49 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.